Genetic mutation increases risk of Parkinson’s disease from pesticides

A team of researchers has brought new clarity to the picture of how gene-environmental interactions can kill nerve cells that make dopamine. Dopamine is the neurotransmitter that sends messages to the part of the brain that controls movement and coordination. Their discoveries, described in a paper published online in Cell today, include identification of a molecule that protects neurons from pesticide damage.

"For the first time, we have used human stem cells derived from Parkinson’s disease patients to show that a genetic mutation combined with exposure to pesticides creates a ‘double hit’ scenario, producing free radicals in neurons that disable specific molecular pathways that cause nerve-cell death," said Stuart Lipton, M.D., Ph.D., professor and director of Sanford-Burnham Medical Research Institute’s Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research and senior author of the study.

Until now, the link between pesticides and Parkinson’s disease was based mainly on animal studies and epidemiological research that demonstrated an increased risk of disease among farmers, rural populations, and others exposed to agricultural chemicals.

In the new study, Lipton, along with Rajesh Ambasudhan, Ph.D., research assistant professor in the Del E. Webb Center, and Rudolf Jaenisch, M.D., founding member of Whitehead Institute for Biomedical Research and professor of biology at the Massachusetts Institute of Technology, used skin cells from Parkinson’s patients that had a mutation in the gene encoding a protein called alpha-synuclein. Alpha-synuclein is the primary protein found in Lewy bodies—protein clumps that are the pathological hallmark of Parkinson’s disease.

Using patient skin cells, the researchers created human induced pluripotent stem cells (hiPSCs) containing the mutation, and then “corrected” the alpha-synuclein mutation in other cells. Next, they reprogrammed all of these cells to become the specific type of nerve cell that is damaged in Parkinson’s disease, called A9 dopamine-containing neurons—thus creating two sets of neurons—identical in every respect except for the alpha-synuclein mutation.

"Exposing both normal and mutant neurons to pesticides—including paraquat, maneb, and rotenone—created excessive free radicals in cells with the mutation, causing damage to dopamine-containing neurons that led to cell death," said Frank Soldner, M.D., research scientist in Jaenisch’s lab and co-author of the study.

"In fact, we observed the detrimental effects of these pesticides with short exposures to doses well below EPA-accepted levels," said Scott Ryan, Ph.D., researcher in the Del E. Webb Center and lead author of the paper.

Having access to genetically matched neurons with the exception of a single mutation simplified the interpretation of the genetic contribution to pesticide-induced neuronal death. In this case, the researchers were able to pinpoint how cells with the mutation, when exposed to pesticides, disrupt a key mitochondrial pathway—called MEF2C-PGC1alpha—that normally protects neurons that contain dopamine. The free radicals attacked the MEF2C protein, leading to the loss of function of this pathway that would otherwise have protected the nerve cells from the pesticides.

"Once we understood the pathway and the molecules that were altered by the pesticides, we used high-throughput screening to identify molecules that could inhibit the effect of free radicals on the pathway," said Lipton. "One molecule we identified was isoxazole, which protected mutant neurons from cell death induced by the tested pesticides. Since several FDA-approved drugs contain derivatives of isoxazole, our findings may have potential clinical implications for repurposing these drugs to treat Parkinson’s."

While the study clearly shows the relationship between a mutation, the environment, and the damage done to dopamine-containing neurons, it does not exclude other mutations and pathways from being important as well. The team plans to explore additional molecular mechanisms that demonstrate how genes and the environment interact to contribute to Parkinson’s and other neurodegenerative diseases, such as Alzheimer’s and ALS.

"In the future, we anticipate using the knowledge of mutations that predispose an individual to these diseases in order to predict who should avoid a particular environmental exposure. Moreover, we will be able to screen for patients who may benefit from a specific therapy that can prevent, treat, or possibly cure these diseases," Lipton said.

Discoveries in How Memories Form Could Help Treat Dementia

Do fruit flies hold the key to treating dementia? Researchers at the University of Houston (UH) have taken a significant step forward in unraveling the mechanisms of Pavlovian conditioning. Their work will help them understand how memories form and, ultimately, provide better treatments to improve memory in all ages.

Gregg Roman, an associate professor of biology and biochemistry at UH, and Shixing Zhang, his postdoctoral associate, describe their findings in a paper titled “Presynaptic Inhibition of Gamma Lobe Neurons Is Required for Olfactory Learning in Drosophila,” appearing Nov. 27 in Current Biology, a scientific bimonthly journal published by Cell Press.

“Memory is essential to our daily function and is also central to our sense of self,” Roman said. “To a large degree, we are the sum of our experiences. When memories can no longer be retrieved or we have difficulty in forming new memories, the effects are frequently tragic. In the future, our work will enable us to have a better understanding of how human memories form.”

Roman and Zhang set about to unravel some of these mysteries by studying the brains of fruit flies (Drosophila). Within the fly brain, Roman says, there are nerve cells that play a role in olfactory learning and memory. Olfactory learning, he says, is an example of classical conditioning first described by Pavlov in his experiment with dogs. In their study, the flies were trained to associate a weak electric shock with an odor. After training, the flies avoided that odor.

“We found that these particular nerve cells – the gamma lobe neurons of the mushroom bodies in the insect brain – are activated by odors. Training the flies to associate an odor with an electric shock changed how these cells responded to odors by developing a modification in gamma lobe neuron activity, known as a memory trace,” he said. “Interestingly, we found that training caused the gamma lobe neurons to be more weakly activated by odors that were not paired with an electric shock, while the odors paired with electric shock maintained a strong activation of these neurons. Thus, the gamma lobe neurons responded more strongly to the trained odor than to the untrained odor.”

The team also showed that a specific protein – the heterotrimeric G(o) protein – is naturally involved in inhibiting gamma lobe neurons. Roman says removing the activity of this protein only within the gamma lobe neurons resulted in a loss of the memory trace and, thus, poor learning. Therefore, inhibiting the release of neurotransmitters from these neurons through the actions of the G(o) protein is key to forming the memory trace and associative memories.

The significance of using fruit flies is that while their brain structure is much simpler with far fewer neurons, the mushroom body is analogous to the perirhinal cortex in humans, which serves the same function of sensory integration and learning. This simplicity allows scientists to gain insights into how memories are acquired, stored and retrieved.

“Drosophila represents the Goldilocks principle of neural research, with sufficient behavioral complexity, while maintaining a huge advantage in neural simplicity,” Roman said. “The complex behaviors allow us to examine many behavioral processes like learning, attention, aggression and addiction-like behaviors, while the simplicity allows us to dissect the crucial neural activities down to single cells. Additionally, Drosophila has the most powerful genetic toolkit available for behavioral experimentation. In using these tools, we are genetically identifying the molecules necessary to perform these behaviors and dissecting the logic of the neural circuits that allow for changes in behavior to occur.”

The pair says all their experience to date suggests the molecules and logic will translate to most animals, including humans, leading to a more complete understanding of how memories form in humans, both at the level of molecules and through the activity of neural circuits.

Brain imaging differences in infants at genetic risk for Alzheimer’s

Researchers from Brown University and Banner Alzheimer’s Institute have found that infants who carry a gene associated with increased risk for Alzheimer’s disease tend to have differences in brain development compared to children without the gene. The study, published in JAMA Neurology, demonstrates some of the earliest developmental differences associated with a gene variant called APOE ε4, a common genotype and a known risk factor for late-onset Alzheimer’s.

The researchers imaged the brains of 162 healthy infants between the ages of two months and 25 months. All of the infants had DNA tests to see which variant of the APOE gene they carried. Sixty of them had the ε4 variant that has been linked to an increased risk of Alzheimer’s. Using a specialized MRI technique, the researchers compared the brains of ε4 carriers with non-carriers. They found that children who carry the APOE ε4 gene tended to have increased brain growth in areas in the frontal lobe, and decreased growth in areas in several areas in the middle and rear of the brain. The decreased growth was found in areas that tend to be affected in elderly patients who have Alzheimer’s disease.

Researchers emphasized that the findings do not mean that any of the children in the study are destined to develop Alzheimer’s or that the brain changes detected are the first clinical signs of the disease. What the findings do suggest, however, is that brains of APOE ε4 carriers tend to develop differently from those of non-ε4 carriers beginning very early in life. It is possible that these early changes provide a “foothold” for the later pathologies that lead to Alzheimer’s symptoms, the researchers say. Information from this study may be an important step toward understanding how this gene confers risk for Alzheimer’s, something that is not currently well understood.

“This work is about understanding how this gene influences brain development,” said Sean Deoni, who oversees Brown University’s Advanced Baby Imaging Lab and was one of the study’s senior authors. “These results do not establish a direct link to the changes seen in Alzheimer’s patients, but with more research they may tell us something about how the gene contributes to Alzheimer’s risk later in life.”

The APOE ε4 variant linked to Alzheimer’s is present in about 25 percent of the U.S. population. Not everyone who carries the gene gets Alzheimer’s, but 60 percent of people who develop the disease have at least one copy of the ε4 gene.

The gene is thought to have several different roles in the blood and brain, some of which remain to be clarified. For instance, it has been shown to participate in regulation of cholesterol, a molecule that is involved in the development of gray matter and white matter brain cells. It has also been shown to participate in the regulation of amyloid, a brain protein that accumulates in Alzheimer’s and is now being targeted by investigational treatments. Studies are needed to clarify the ways in which APOE, human development, aging and other risk factors may conspire to produce the brain changes involved in Alzheimer’s disease.

The researchers used an MRI technique developed at Brown’s Advanced Baby Imaging Lab. The technique quiets the MRI machine to a whisper, enabling the brains of healthy babies to be imaged while they sleep without medication. The technique also enables imaging of both gray matter — the part of the brain that contains neurons and nerve fibers — and white matter, which contains the fatty material that insulates the nerve fibers. Both gray and white matter are thought to have a role in Alzheimer’s. White matter growth begins shortly after birth and is an important measure of brain development.

“We’re in a good spot to be able to investigate how this gene influences development in healthy infants,” said Deoni, assistant professor of engineering at Brown. “These infants are not medicated and not showing any cognitive decline — quite the opposite, actually; they’re developing normally.”

There is no reason to believe that the children won’t continue to develop normally, Deoni said. There is no consistent evidence to suggest that ε4 carriers suffer any cognitive problems or developmental delay. And the areas of increased growth raise the possibility that the gene might actually confer some advantages to infants early on. Utimately the researchers hope the findings could lead to new strategies for preventing a disease that currently affects more than 5.2 million people in the U.S. alone.

“It may sound scary that we could detect these brain differences in infants,” said Dr. Eric Reiman, executive director of the Banner Alzheimer’s Institute in Arizona and another senior author on the paper. “But it is our sincere hope that an understanding of the earliest brain changes involved in the predisposition to Alzheimer’s will help researchers find treatments to prevent the clinical onset of Alzheimer’s disease — and do so long before these children become senior citizens.”

Breaking the Brain Clock Predisposes Nerve Cells to Neurodegeneration

As we age, our body rhythms lose time before they finally stop. Breaking the body clock by genetically disrupting a core clock gene, Bmal1, in mice has long been known to accelerate aging , causing arthritis, hair loss, cataracts, and premature death.

New research now reveals that the nerve cells of these mice with broken clocks show signs of deterioration before the externally visible signs of aging are apparent, raising the possibility of novel approaches to staving off or delaying neurodegeneration – hallmarks of Parkinson’s and Alzheimer’s diseases.

Erik Musiek, M.D., Ph.D., who was a postdoctoral fellow in the lab of Garret FitzGerald, M.D., director of the Institute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, took on this project four years ago. Musiek, now an assistant professor at Washington University, completed this line of research over the last two years in the lab of David Holtzman, M.D., also at WashU.

The Penn-WashU team found that the expression of certain clock genes, including Bmal1, plays a fundamental role in delaying emergence of age-related signs of decay in the brain. The clock proteins appear to do this by protecting the brain against oxidative stress – a process akin to rusting – that is normally controlled by enzymes that degrade harmful forms of oxygen generated in the course of normal metabolism. Their findings appear this week in the Journal of Clinical Investigation.

 “I had lunch with Garret four years ago when I was a resident in neurology at Penn and this led me to work in his lab,” recalls Musiek. “He had studied oxidative stress in cells and the lab was actively pursuing the role of the molecular clock in cardiovascular and metabolic function. However, he hadn’t studied the brain nor the role of the clock as a regulator of oxidative stress. Others had connected the clock to signs of aging, but hadn’t focused on the brain - it seemed like an opportunity to pursue.”

They found, to their surprise, that inflammation – reflected by activation of astrocytes – brain cells involved in this type of response, among other functions — was marked in young mice in which the clock was broken by deleting Bmal1. This anticipated even more marked changes in brain pathology as the mice aged, including declines in how parts of the brain connected to each other and degenerative features in nerve-cell anatomy – all characteristic of Parkinsons and Alzheimer’s disease in humans.

“When we saw this, we knew we were on to something,” notes Musiek.

Further experiments revealed that these effects were not restricted to disrupting the function of Bmal1, but also occurred when genes – Clock and Npas2 – with which Bmal1 works in tandem, were both removed. By contrast, deletion of other genes in the clock apparatus had no such effect.

As for mechanism, the exaggerated rusting, or oxidation, was key. Expression of several antioxidant enzymes, which normally keep oxidant stress in check are themselves controlled by clock proteins, and thus were depleted when the clock was broken. Musiek and his colleagues found evidence that inflammation and the attendant oxidant stress were both increased in the brains of the mutant mice.

Experimental drugs are beginning to emerge that may retain waning rhythms driven by the molecular clock. “Erik’s studies raise the intriguing possibility of novel therapeutic approaches to delaying the progress of age-related diseases, perhaps not only those related to the brain, as suggested by the present studies, but also in other systems, such as cardiometabolic function,” says FitzGerald.

In a final twist, the Penn-WashU team pinned the neuroprotective role of the body clock to clock genes in neurons and astrocytes, rather than changes in whole-animal circadian rhythms. By selectively deleting Bmal1 in these cell types, they found that the inflammatory aspects of astrocytes, neurodegeneration, and hallmarks of oxidative stress and inflammation seen when Bmal1 was missing in all cells of the body was recapitulated.

 “Our findings indicate that the protein complex of BMAL1 with CLOCK or NPAS2, in addition to, or perhaps intrinsic to the complex’s internal body-clock function, regulates protection of the brain from inflammation and oxygen free-radical induced damage. This dynamic system connects impaired clock-gene function to neurodegeneration for the first time,” says Musiek.

Not So Dumb

Mysterious brain cells called microglia are starting to reveal their secrets thanks to research conducted at the Weizmann Institute of Science.

Until recently, most of the glory in brain research went to neurons. For more than a century, these electrically excitable cells were believed to perform the entirety of the information processing that makes the brain such an amazing machine. In contrast, cells called glia – which together account for about half of the brain’s volume – were thought to be mere fillers that provided the neurons with support and protection but performed no vital function of their own. In fact, they had been named glia, the Greek for “glue,” precisely because they were considered so unsophisticated.

But in the past few years, the glia cells – particularly the tiny microglia that make up about one-tenth of the brain cells – have been shown to play critical roles both in the healthy and in the diseased brain.

The octopi-like microglia are immune cells that conduct ongoing surveillance, swallowing cellular debris or, in the case of infection, microbes, to protect the brain from injury or disease. But these remarkable cells are more than cleaners: In the past few years, they have been found to be involved in shaping neuronal networks by pruning excessive synapses – the contact points that allow neurons to transmit signals – during embryonic development. They are probably also involved in reshaping the synapses as learning and memory occurs in the adult brain. Defects in microglia are believed to contribute to various neurological diseases, among them Alzheimer’s disease and amyotrophic lateral sclerosis, or ALS. By clarifying how exactly the microglia operate on the molecular level, scientists might be able to develop new therapies for these disorders.

More than a decade ago, Weizmann Institute’s Prof. Steffen Jung developed a transgenic mouse model that for the first time enabled scientists to visualize the highly active microglia in the live brain. Now Jung has made a crucial next step: His laboratory developed a system for investigating the functions of microglia.

The scientists have equipped mice with a genetic switch: an enzyme that can rearrange previously marked portions of the DNA. The switch is activated by a drug: When the mouse receives the drug, the enzyme performs a genetic manipulation – for example, to disable a particular gene. The switch is so designed that over the long term, it targets only the microglia, but not other cells in the brain or in the rest of the organism. In this manner, researchers can clarify not only the function of the microglia, but the roles of different genes in their mechanism of action.

As reported in Nature Neuroscience, Weizmann scientists, in collaboration with the team of Prof. Marco Prinz at the University of Freiburg, Germany, recently used this system to examine the role of an inflammatory gene expressed by the microglia. They found that the microglia contribute to an animal disease equivalent of multiple sclerosis. Prof. Jung’s team included Yochai Wolf, Diana Varol and Dr. Simon Yona, all of Weizmann’s Immunology Department.

Common brain cell plays key role in shaping neural circuit

Stanford University School of Medicine neuroscientists have discovered a new role played by a common but mysterious class of brain cells.

Their findings, published online Nov. 24 in Nature, show that these cells, called astrocytes because of their star-like shape, actively refine nerve-cell circuits by selectively eliminating synapses — contact points through which nerve cells, or neurons, convey impulses to one another — much as a sculptor chisels away excess bits of rock to create an artwork.

“This was an entirely unknown function of astrocytes,” said Ben Barres, MD, PhD, professor and chair of neurobiology and the study’s senior author. The lead author was Won-Suk Chung, PhD, a postdoctoral scholar in Barres’ lab. More than one-third of all the cells in the human brain are astrocytes. But until quite recently, their role in the brain has remained obscure.

The study was performed on brain tissue from mice, but it is likely to apply to people as well, Barres said.

The discovery adds to a growing body of evidence that substantial remodeling of brain circuits takes place in the adult brain and that astrocytes are master sculptors of its constantly evolving synaptic architecture. The findings also raise the question of whether deficits and excesses in this astrocytic function could underlie, respectively, the loss of this remodeling capacity in old age or the wholesale destruction of synapses that erupts in neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease.

“Astrocytes are in the driver’s seat when it comes to synapse formation, function and elimination,” Barres said. In previous studies, he and his colleagues have shown that astrocytes play a critical role in determining exactly where and when new synapses are generated.

The new study showed that astrocytes’ synapse-gobbling behavior persists into adulthood and is triggered by activity in the neurons, suggesting astrocytes may be central to the constant fine-tuning and reconfiguring of brain circuits occurring throughout our lives in response to experiences such as learning, recollection, emotion and motion. While a healthy brain’s neurons remain intact for much a person’s lifetime, the connections between them — the synapses — are constantly forming, strengthening, weakening or dying.

The Barres team also has previously implicated another brain cell type, collectively known as microglia, in synaptic pruning in early development, when the young brain undergoes ongoing episodes of circuit remodeling. The role of astrocytes in synaptic refining, the new study shows, differs from that of microglia both in timing and mechanism.

Barres’ team began to suspect astrocytes’ participation in the pruning process when, having developed methods for isolating exceptionally pure populations of different types of brain cells, they saw that the genes for two separate biochemical pathways were active in astrocytes. Both of these pathways are involved in phagocytosis, the trash-collection process by which specialized cells in the body engulf, ingest and digest dead cells; foreign materials, including bacteria; debris from wounds; and so forth. At the leading end of the two pathways were two phagocytic receptors, MERKTK and MEGF10, which in other cell types have been shown to bind to particular proteins on targeted cells or materials, triggering the ensuing engulfment, ingestion and digestion of the targets.

It’s known that much of an astrocyte’s surface membrane is typically in close contact with neurons. In fact, a single astrocyte may ensheathe thousands of synapses. It was only natural, Barres said, to wonder whether astrocytes play some role in eliminating synapses.

The researchers first demonstrated that both MERKTK and MEGF10, along with their entire tool kits of cooperating proteins, are present in living astrocytes in the mouse brain. (In unpublished work, they have since confirmed this using human astrocytes.) Next, they showed that mouse astrocytes in a lab dish eagerly gobbled up synapses and dispatched them to their lysosomes, highly acidic internal garbage disposals found in most cells in the body. But this engulfment was dependent on astrocytes having functional MEGF10 and MERTK. Disabling one or the other receptor’s function cut in half astrocytes’ ability to engorge themselves on synapses; knocking out both receptors lowered the synapse-eating activity by about 90 percent.

To see if this happens in real life, Chung, Barres and their associates turned to a familiar experimental model: a brain area called the lateral geniculate nucleus, which is a critical component of the brain’s vision-processing system. The LGN receives inputs from neurons just a couple of steps downstream from the photoreceptors in the retina. In early development, neurons in the LGN are innervated by inputs from both eyes. But at a critical point in development, a highly selective synaptic-pruning process kicks in, resulting in each neuron from one side of the LGN being contacted pretty much only by neurons from a single eye. This pruning process in the LGN is dependent on the transmission of waves of spontaneous neuronal impulses originating in the retina.

Experimenting with mice that had entered the critical period for synaptic pruning in the LGN, the investigators labeled the incoming neurons in this system with different-colored stains so their synaptic regions could be identified within astrocytes if the astrocytes ate them up. And sure enough, a lot of this label turned up inside astrocytes’ lysosomes, indicating that astrocytes were actively ingesting synapses. Knocking out one or another or, especially, both of the two phagocytic receptors greatly reduced the amount of labeled synaptic material found in astrocytes. Impairing astrocytic MERKTK and MEGF10 function also caused a failure of LGN neurons to restrict their inputs to only neurons from just one eye, clearly implicating astrocytes in that process. Electrophysiology experiments proved that the LGN neurons in the MERKTK- and MEGF10-knockout mice retained an excessive number of synapses, demonstrating that astrocytes play an active role in pruning synapses during development.

Importantly, injection of a drug blocking the transmission of spontaneous waves of electrical impulses originating in the retina severely impaired astrocytes’ ability to eat synapses, showing that the synapse-pruning propensity is linked to neuronal activity. Other tests showed that astrocytic phagocytosis of synapses continues into adulthood.

Barres said this raises the question of whether astrocytes function throughout life to continually restructure our neuronal circuitry in response to experientially induced brain activity. If astrocytes’ synaptic snacking slows with aging, as that of other phagocytic cell types is known to do, it could reduce the aging brain’s capacity to adapt to new experiences, he said. “Maybe you need the astrocytes to gobble up old synapses to make room for new ones.”

If so, it may be possible someday to design drugs to keep astrocytes’ phagocytic process from slowing, Barres added. Such drugs might prevent the accumulation in aging brains of past-their-prime synapses, which are vulnerable to degeneration in Alzheimer’s, Parkinson’s and other neurodegenerative disease characterized by massive synapse loss.

(Image credit)